Edesa Biotech, Inc.
For the period ended Aug 19, 2026. Filed Aug 20, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 19, 2026 · Filed Aug 20, 2026
Use the contents to explore the available documents and sections.
Contents
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of proceeds expected from the Offering, the intended use of proceeds from the Offering and the timing and certainty of completion of the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the proposed restructuring of the Company’s outstanding indebtedness, the Company’s ability to complete the Offering on favorable terms, or at all, as well as other risks detailed from time to time in the Company’s filings with the SEC, including in its Annual Report on Form 10-K for the year ended September 30, 2025 and the Prospectus Supplement. These documents contain important factors that could cause actual results to differ from current expectations and from the forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
| 1.1 | Underwriting Agreement, dated August 19, 2026, by and between the Company and Guggenheim Securities, LLC. |
| 4.1 | Form of Common Share Warrant. |
| 4.2 | Form of Pre-Funded Warrant. |
| 5.1 | Opinion of Fasken Martineau DuMoulin LLP. |
| 5.2 | Opinion of Lowenstein Sandler LLP. |
| 23.1 | Consent of Fasken Martineau DuMoulin LLP (included in Exhibit 5.1). |
| 23.2 | Consent of Lowenstein Sandler LLP (included in Exhibit 5.2). |
| 99.1 | Press release dated August 19, 2026. |
| 99.2 | Press release dated August 19, 2026. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.